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Interleukin (IL)–10 directly inhibits human immunodefi-
ciency virus type 1 (HIV-1) replication, but it may also pro-
mote viral persistence by inactivation of effector immune
mechanisms. Here, we show in an African cohort that in-
dividuals with genotypes associated with high IL-10 produc-
tion at 2 promoter single-nucleotide polymorphisms (1082
and 592) were less likely to become HIV-1 infected but had
significantly higher median plasma viral loads during the
acute phase (3 months after infection). However, as the
infection progressed, the association between genotype and
median viral load was reversed. Thus, IL-10 may influence
HIV-1 susceptibility and pathogenesis, but effects on the lat-
ter may differ according to the infection phase.
The interleukin-10 (IL-10) proximal promoter region contains
2 biallelic polymorphisms at positions 1082 (A to G transi-
tion) and 592 (C to A transversion), which are related to
levels of IL-10 production [1, 2]. Polymorphisms associated
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with decreased IL-10 production have been associated with an
increased likelihood of human immunodeficiency virus type 1
(HIV-1) acquisition and an accelerated rate of CD4+ T cell
decline, particularly in late-stage disease [3, 4], suggesting that
high IL-10 production may reduce susceptibility to HIV-1 in-
fection and protect against disease progression. Paradoxically,
2 recent studies of lymphocytic choriomeningitis virus (LCMV)
in mice, a model of chronic viral infections, have demonstrated
that removal of IL-10 or blockade of the IL-10 pathway may
enhance T cell immune responses, resulting in the rapid elim-
ination of virus and the development of antiviral memory T
cell responses and culminating in LCMV clearance [5, 6]. The
effect of IL-10 on HIV-1 replication in vivo is further com-
plicated by the observation that the cytokine directly inhibits
HIV-1 replication in human macrophages [7, 8]. The inhibitory
effects of IL-10 on HIV-1 replication may become more pro-
nounced in late stages of disease, when CD4+ lymphocytes are
depleted and replication in macrophages and monocytes pre-
dominates [9–11].
This study was undertaken to gain better insight into the
complex role of IL-10 in HIV-1 infection and pathogenesis.
Specifically, we investigated whether genetic polymorphisms in
the proximal region of the IL-10 gene promoter contribute to
HIV-1 susceptibility and to primary HIV-1 pathogenesis in an
African cohort at high risk for infection.
Subjects, materials, and methods. The Centre for the AIDS
Programme of Research in South Africa (CAPRISA) acute in-
fection cohort was described in detail elsewhere [12]. This lon-
gitudinal cohort study on viral set point and clinical progres-
sion in HIV-1 subtype C infection was established in Durban,
South Africa, in 2004. The cohort comprised 245 high-risk
HIV-negative women who were screened monthly for HIV in-
fection using 2 rapid antibody tests (Determine, Abbott Lab-
oratories; Capillus, Trinity Biotech). Negative or indetermi-
nate samples were subjected to pooled plasma polymerase
chain reaction (PCR) testing, and positive pools were decon-
structed and individually tested (COBAS AmpliScreen HIV-1
test, Roche Diagnostics). HIV-1 infection was further con-
firmed in RNA-positive samples with an HIV enzyme immu-
noassay test (Enzygnost), and a diagnostic nucleic acid test
(Roche). CD4+ T cell counts were determined by flow cytom-
etry (Becton Dickinson).
Twenty-eight seroconverters from the HIV-negative cohort
and 36 individuals from other seroincidence cohorts were en-
rolled into the acute infection phase (phase II) of the study.
Once enrolled into phase II, participants were seen weekly for
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3 weeks, then fortnightly for 2 months, then monthly for 10
months, and quarterly thereafter. Thirty-nine participants in
the HIV-negative cohort ( ) were unavailable for follow-n p 245
up. In the HIV-positive cohort, 8 participants exited the study;
1 refused participation, 2 died accidentally, and 5 had to begin
antiretroviral treatment. At the time of assessment, there were
a total of 281 individuals in the study, of whom 259 had samples
available for assessment. Sixty-four of 259 had acquired HIV-
1 infection. Ethics approval was obtained from the ethics com-
mittee of the University of KwaZulu-Natal, and participants
provided informed consent.
Genotype assessments for the 2 proximal IL-10 promoter
single-nucleotide polymorphisms (SNPs; 1082 and 592 rel-
ative to the transcription start site) were performed using am-
plification refractory mutation system PCR, as described else-
where [13].
The x2 test was used to compare allelic frequencies, confirm-
ing their fit to Hardy-Weinberg equilibrium. Fisher’s exact test
was used to analyze the association between HIV status and
IL-10 polymorphic variants. Kaplan-Meier survival statistics
and Cox proportional hazards model were used to assess the
time to HIV-1 infection. Generalized estimating equation (GEE)
models were used to compare the longitudinal measurements
of viral loads and CD4+ counts between different genotype
groups. The GEE models were univariate models, unadjusted
for other covariates but taking into account repeated measures.
The covariance matrix for the GEE model was unstructured.
Haplotype effects were analyzed by fitting the haplotype prob-
abilities as continuous variables to viral load and CD4 counts,
using GEE models.
Results. The mutant allele frequencies at SNPs 1082 and
592 in our cohort were 0.33 and 0.32, respectively. Allele
frequencies were confirmed by x2 tests to be in Hardy-Weinberg
equilibrium for the entire cohort and for subgroups analyzed
in this study. Linkage disequilibrium estimates between the 2
SNPs were calculated, using Haploview, as and2r p 0.12
[14]. The SNPs specified 4 haplotypes, termed 1′D p 0.70
(AC), 2 (AA), 3 (GC), and 4 (GA), which occurred at ap-
proximate frequencies of 37%, 30%, 29%, and 3%, respectively.
There was no significant difference in the distribution of IL-
10 genotypes for the 1082 position between HIV-1–negative
and HIV-1–positive groups ( ) (figure 1A). For the 222P p .144
participants who were enrolled while HIV negative and who
were followed up prospectively, Kaplan-Meier survival analysis
of time to HIV-1 seroconversion for genotypes at the 1082
position (figure 1B) showed no significant differences in the
risk of HIV-1 acquisition between genotype 1082AA and ge-
notype 1082GG or 1082AG. Using the Cox proportional
hazards model, if an individual carried the 1082AA genotype
the hazard ratio of becoming HIV-1 infected was 2.14 (95%
confidence interval [CI], 0.99–4.63; ).P p .054
However, there was a significant association between HIV-1
status and the IL-10 592 genotype (figure 1C), owing to the
large proportion of HIV-positive individuals who carried the
592AA genotype, compared with the other genotypes (P p
). In the analysis of high-risk HIV-1–negative individuals.003
followed up prospectively, those with the 592AA genotype
were significantly more likely to become HIV infected than
were those with the 592CA or 592CC genotype (figure 1D).
Using the Cox proportional hazards model, individuals with
the 592AA genotype were at increased risk of becoming HIV
infected (hazard ratio, 3.0; 95% CI, 1.28–7.08; ).P p .012
Three haplotypes in this cohort had frequencies of 15%:
haplotypes 1, 2, and 3. Only haplotypes 2 and 3 showed sig-
nificant association with HIV-1 status. In normal logistic re-
gression analysis, haplotype 2, predicted to result in low IL-10
production, was associated with a 1.8-fold greater likelihood
of being HIV positive (95% CI, 1.21–2.74; ). In con-P p .004
trast, haplotype 3 (high IL-10 producer) was associated with a
0.59-fold lower likelihood of HIV acquisition (95% CI, 0.36–
0.96; ).P p .032
For the 64 individuals who became infected with HIV-1, we
investigated whether viral load and CD4+ T cell counts differed
between the phases of infection according to IL-10 genotypes.
At 3 months after infection (the acute phase) and 6–12
months after infection (the early chronic phase), we compared
median viral loads and CD4+ T cell counts between the 3 ge-
notypic groups for both SNPs at positions 1082 and 592
(figure 2).
Analysis of the overall change in viral load based on the
1082 genotype (figure 2A) shows that individuals with the
1082GG genotype (high IL-10 producer) had significantly
higher median viral loads during the acute phase than those
with the 1082AA ( ) or 1082AG ( ) geno-P ! .001 P p .003
type. During the early chronic phase, however, there was no
longer a significant difference between the 3 groups. Analysis
of the overall change in CD4+ T cell count (figure 2B) showed
that during the acute phase, the 1082GG group had the lowest
median CD4+ T cell count and that it was significantly different
from that in the 1082AA group ( ). In comparison,P p .012
during the early chronic phase of infection, the 1082GG
group was not significantly different from the other groups.
During the acute phase, the 592CC group (ie, high IL-10
producers) did not have significantly different median viral
loads than the 592CA and 592AA groups ( andP p .129
.059, respectively) (figure 2C). During the early chronic phase,
the 592AA group (ie, low IL-10 producers) had a significantly
higher median viral load than the 592CA and 592CC
groups ( and .008, respectively). However, there wereP p .002
no significant differences in CD4+ T cell counts between 592
variants during either the acute or early chronic phase of in-
fection (figure 2D).
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Figure 1. The influence of interleukin (IL)–10 promoter polymorphisms on human immunodeficiency virus type 1 (HIV-1) susceptibility. A, Association
of 1082 genotype and HIV status. The distribution of genotypes for the 1082 position, based on HIV status, showed no significant association
between IL-10 genotypes and HIV-1 status. B, Kaplan-Meier graph, analyzing time to infection, showing no significant differences between 1082
genotypes, although there was a trend toward higher likelihood of infection for the 1082AA genotype. C, Distribution of genotypes for the 592
position, based on HIV status, showing a significant association between IL-10 genotype and HIV status, because of the large number of HIV-positive
individuals in the 592AA group ( ). D, Kaplan-Meier graph of time to infection showing that individuals with the 592AA genotype wereP p .003
significantly more likely to become HIV infected ( ).P p .012
During the acute phase of infection, haplotype 2 trended
toward a negative effect on viral load ( ), whereas hap-P p .081
lotype 3 had a significantly positive effect ( ). However,P ! .001
during the early chronic phase, haplotype 2 had a significantly
positive effect on viral load ( ), and the positive effectP ! .001
of haplotype 3 was no longer significant ( ).P p .493
Discussion. Recently, the immunoregulatory cytokine IL-
10 was identified as playing a key role in suppressing antiviral
immune responses, leading to viral persistence [5, 6]. Neu-
tralization of IL-10 has also been shown to result in enhanced
T cell immune responses and viral clearance in the LCMV
model of chronic viral infection [15]. However, 2 HIV-1 natural
history studies of genetic polymorphisms in the IL-10 promoter
appear to run counter to these recent findings by demonstrating
that IL-10 promoter genetic polymorphisms associated with
higher IL-10 production attenuate CD4+ T cell loss and are
protective against disease progression, albeit in long-term fol-
low-up cohorts [5, 6].
In our South African cohort, carriers of the 592AA ge-
notype were more likely to become HIV-1 infected. Our results
are in agreement with those of Shin et al. [4], who demonstrated
in a North American cohort that carriers of the 592A allele
were at higher risk of HIV acquisition than individuals carrying
the wild-type allele. These results generally suggest that IL-10
promoter polymorphisms linked to low IL-10 production are
associated with increased HIV-1 susceptibility, although the ef-
fect of the 592 SNP appears to be stronger than that of the
1082 SNP, because the trend for the latter SNP did not reach
statistical significance. These results are reinforced by the ob-
servation that lower IL-10 producer haplotypes were signifi-
cantly more likely to become HIV-1 infected.
We also investigated the influence of IL-10 proximal pro-
moter polymorphisms on primary HIV-1 pathogenesis. Gen-
erally, we found that higher-producing IL-10 polymorphisms
were associated with high viral load during the acute infection
phase. However, as infection progressed toward the chronic
BRIEF REPORT • JID 2009:200 (1 August) • 451
Figure 2. Influence of interleukin (IL)–10 promoter polymorphisms on primary human immunodeficiency virus type 1 (HIV-1) pathogenesis. A, Overall
change in viral load (VL) over time, based on 1082 genotype. During the first 3 months after infection, the median viral load of the 1082GG group
was significantly higher than those of the 1082AA and 1082AG groups ( and , respectively). After 6 months, there was noP ! .001 P p .003
significant difference in median viral loads between the 1082GG group and either the 1082AA ( ) or 1082AG ( ) group. B,P p .758 P p .280
Overall change in CD4+ T cell count over time, by 1082 genotype. During the first 3 months after infection, the 1082GG group had a significantly
lower median CD4+T cell count than the 1082AA group ( ). After 6 months, the median CD4+ T cell count in the 1082GG group was notP p .012
significantly different from that in the 1082AA or 1082AG group ( and , respectively). C, Overall change in viral load over time,P p .274 P p .474
based on 592 genotype. During the first 3 months after infection, the median viral load in the 592CC group was not significantly different from
that in the 592AA or 592CA group ( and , respectively). After 6 months, the median viral load in the 592AA group wasP p .059 P p .129
significantly different from those in the 592CC and 592CA groups ( and , respectively). D, Overall change in CD4+ T cell countP p .008 P p .002
over time, by 592 genotype. There was no significant difference in median CD4+ T cell count between groups at either the acute or the early chronic
phase of infection.
phase, differences in viral load between the genotype groups
either disappeared or reversed. Thus, during the acute phase
of HIV-1 infection, our data are consistent with recent data in
the LCMV model, in which IL-10 was shown to be a key player
in inhibiting effector immune responses, leading to increased
viral replication and persistence [5, 6] . However, as infection
proceeded toward the chronic phase, we observed that viral
load differences between genotypes disappeared, or a poly-
morphism associated with increased IL-10 production was also
associated with lower plasma viral load and increased CD4+ T
cell count. We interpret this result to suggest that, as HIV-1
infection progresses to a chronic state, IL-10 may have a pro-
tective role against CD4+ T cell loss and disease progression.
This is in agreement with previous findings demonstrating that
IL-10 promoter polymorphisms linked with increased IL-10
production are protective against CD4+ T cell loss and disease
progression [3, 4]. We acknowledge that our data need to be
interpreted cautiously, given the small sample size of this study
and the short follow-up period of the cohort. It is also obvious
that mechanistic studies are needed to investigate the role of
IL-10 in immune activation and HIV-1 replication in different
phases of HIV-1 infection.
In conclusion, we propose a model for the role of IL-10 in
HIV-1 susceptibility and disease progression, whereby high lev-
els of IL-10 protect against HIV-1 infection, possibly by re-
ducing immune activation and counteracting inflammatory
processes that increase the pool of susceptible cells, and low
levels of IL-10 may have the opposite effects. In acute HIV-1
infection, high IL-10 levels may promote viral replication by
dampening innate and adaptive effector immune responses in
a manner similar to that described for the LCMV model [5,
6]. Furthermore, we propose that, in chronic HIV-1 infection—
particularly during the late stages of disease—IL-10 may be
protective by reducing immune activation and inhibiting HIV-
1 replication in macrophages. Given the importance of un-
derstanding the role of immune activation and dysregulation
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in driving HIV-1 infection and pathogenesis, and considering
that IL-10 has been reported as an integral player in these
processes, the model proposed here warrants experimental
scrutiny.
Acknowledgments
We thank the study participants and CAPRISA clinical and laboratory
staff for providing specimens. We give special acknowledgments to the
following members of the CAPRISA Acute Infection Study team: Carolyn
Williamson, Lynn Morris, Clive Gray, Winston Hide, and Francois van
Loggerenberg.
References
1. Kamali-Sarvestani E, Kiany S, Gharesi-Fard B, Robati M. Association
study of IL-10 and IFN-gamma gene polymorphisms in Iranian women
with preeclampsia. J Reprod Immunol 2006; 72:118–26.
2. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the
Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood
2006; 107:4101–8.
3. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, et al. Reduced mortality
and CD4 cell loss among carriers of the interleukin-10 -1082G allele
in a Zimbabwean cohort of HIV-1-infected adults. AIDS 2007; 21:
2283–91.
4. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1
pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci
USA 2000; 97:14467–72.
5. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Old-
stone MB. Interleukin-10 determines viral clearance or persistence in
vivo. Nat Med 2006; 12:1301–9.
6. Ejrnaes M, Filippi CM, Martinic MM, et al. Resolution of a chronic
viral infection after interleukin-10 receptor blockade. J Exp Med
2006; 203:2461–72.
7. Ancuta P, Bakri Y, Chomont N, Hocini H, Gabuzda D, Haeffner-
Cavaillon N. Opposite effects of IL-10 on the ability of dendritic cells
and macrophages to replicate primary CXCR4-dependent HIV-1
strains. J Immunol 2001; 166:4244–53.
8. Wang Y, Rice AP. Interleukin-10 inhibits HIV-1 LTR-directed gene
expression in human macrophages through the induction of cyclin T1
proteolysis. Virology 2006; 352:485–92.
9. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during
opportunistic infections. Science 1997; 276:1857–61.
10. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte
chemotaxis and activation by infected macrophages. Nat Med 1999;
5:997–103.
11. Verani A, Gras G, Pancino G. Macrophages and HIV-1: dangerous
liaisons. Mol Immunol 2005; 42:195–212.
12. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a
cohort at high risk of HIV infection in South Africa: challenges and
experiences of the CAPRISA 002 Acute Infection Study. PLoS ONE
2008; 3:e1954.
13. Opdal SH, Opstad A, Vege A, Rognum TO. IL-10 gene polymorphisms
are associated with infectious cause of sudden infant death. Hum Im-
munol 2003; 64:1183–9.
14. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visual-
ization of LD and haplotype maps. Bioinformatics 2005; 21:263–5.
15. Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB. IL-
10 blockade facilitates DNA vaccine-induced T cell responses and en-
hances clearance of persistent virus infection. J Exp Med 2008; 205:
533–41.
